Genetic analytics company 23andMe reported via a regulatory filing that it had raised $79 million in a Series E venture capital round that could eventually hit $150 million. Market research firm VC Experts subsequently pulled Delaware filings that show the round was done at a post-money valuation of approximately $1.03 billion (based on the $79m, not the $150m).
That’s nearly a 2.7x valuation jump from 23andMe’s Series D raise, which occurred in late 2012. Investors on that round included Google Ventures, New Enterprise Associates, MPM Capital and Yuri Milner.
So how do we explain the valuation jump, particularly given that 23andme last year was dealt a severe blow when the FDA said it could no longer market its personalized DNA testing kit for health reports to U.S. consumers?
Share this article
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: 23andMe is the startup world’s newest unicorn
